Vibration Response Imaging (VRI) in Dyspnea Patients Presenting to the ED
Assessment of the Utility of Vibration Response Imaging (VRI) in Evaluating Dyspnea Patients Presenting to the Emergency Department
1 other identifier
observational
530
2 countries
8
Brief Summary
For the patient with acute dyspnea in the ED, early differentiation between CHF and non-CHF causes is essential for proper management. The capacity to triage patients quickly and accurately has a beneficial impact upon outcome, disposition, stratification and length of stay in the ED and required length of hospital admission. The ability to assess pulmonary status rapidly by quantitative regional vibration technology offers significant potential advantage for earlier diagnosis. The VRI technique may provide a quick and accurate method of differentiating between dyspnea due to HF and dyspnea due to pulmonary causes; thereby improving management and outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2010
Shorter than P25 for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2010
CompletedFirst Submitted
Initial submission to the registry
September 21, 2010
CompletedFirst Posted
Study publicly available on registry
September 22, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2011
CompletedMay 13, 2011
September 1, 2010
10 months
September 21, 2010
May 12, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assess the ability of the VRI to improve clinical outcomes via accurate, early classification of the cause of acute dyspnea as HF or other (i.e. COPD, PE etc).
The primary efficacy analysis set (PEAS) consists of all patients who have Gold Standard (GS) diagnosis (CHF/non-CHF) \& VRI records. * Accuracy rate is defined as the accuracy between the GS and VRI. * Accuracy parameters between the GS and VRI will be calculated using accuracy rate, sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) \& likelihood ratios (+,-).
Baseline testing at ED presentation
Secondary Outcomes (3)
Assess the agreement to aid in classifying the cause of acute dyspnea as HF or other of the VRI in comparison to BNP/NTproBNP assays.
Baseline testing at ED presentation
Assess the ability of the VRI to aid in classifying the cause of acute dyspnea as HF or COPD
Baseline testing at ED presentation
Evaluate the ability of the VRI to monitor changes in clinical status following treatment in comparison with other standard testing methods (e.g. ECG, serial chest x-rays, etc.)
Baseline testing and repeated testing after 2 hours
Study Arms (1)
ED patients presenting with dyspnea
Eligibility Criteria
Patients presenting to the ED with acute dyspnea who are greater than 40 years of age and consisting of both male and females
You may qualify if:
- Able and willing to provide Informed Consent;
- \>40 years of age;
- Estimated Body Mass Index \>19;
- Patient presented to the emergency department with a chief complaint of acute dyspnea.
You may not qualify if:
- Patients with obvious trauma or acute anxiety as a cause of dyspnea;
- Patient has already received directed therapy in the ED and symptoms are remarkably improved;
- Physician concern regarding possible harm to patient caused by positioning or ambulating the patient for VRI testing;
- Intubated or mechanically ventilated;
- Acute hemodynamic or ventilator instability requiring immediate resuscitation;
- Body habitus or skin condition that might prevent the placement of the sound sensors on the back (e.g. severe scoliosis, kyphosis, chest wall deformation, skin lesion on the back or compression fracture);
- Hirsutism.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Deep Breezelead
Study Sites (8)
Christiana Care Health System
Newark, Delaware, 19718, United States
University of Nevada School of Medicine
Las Vegas, Nevada, 89106, United States
Mount Sinai School of Medicine
New York, New York, 10029, United States
Lincoln Medical and Mental Health Center
The Bronx, New York, 10451, United States
Metrohealth Medical Center
Cleveland, Ohio, 44122, United States
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
Beilinson Hospital, Rabin Medical Center
Petah Tikva, 49100, Israel
Related Publications (3)
Wang Z, Bartter T, Baumann BM, Abouzgheib W, Chansky ME, Jean S. Asynchrony between left and right lungs in acute asthma. J Asthma. 2008 Sep;45(7):575-8. doi: 10.1080/02770900802017744.
PMID: 18773329BACKGROUNDGuntupalli KK, Reddy RM, Loutfi RH, Alapat PM, Bandi VD, Hanania NA. Evaluation of obstructive lung disease with vibration response imaging. J Asthma. 2008 Dec;45(10):923-30. doi: 10.1080/02770900802395496.
PMID: 19085584BACKGROUNDDellinger RP, Parrillo JE, Kushnir A, Rossi M, Kushnir I. Dynamic visualization of lung sounds with a vibration response device: a case series. Respiration. 2008;75(1):60-72. doi: 10.1159/000103558. Epub 2007 Jun 4.
PMID: 17551264BACKGROUND
Biospecimen
Blood drawn for BNP testing
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Charles V. Pollack, MD
Pennsylvania Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 21, 2010
First Posted
September 22, 2010
Study Start
August 1, 2010
Primary Completion
June 1, 2011
Study Completion
June 1, 2011
Last Updated
May 13, 2011
Record last verified: 2010-09